Foresite Capital Management VI LLC: 13F holdings
CIK 20133412026Q2
| Positions | 23 |
|---|
| Reported value | $642.6m |
|---|
| Filed | 2026-08-14 |
|---|
Change since last quarter
| Positions | 23 (+6 vs prior quarter) |
|---|
| Reported value | $642.6m (+39.6%) |
|---|
Top 10 holdings
| Security | Shares | Value | Weight |
|---|
| CGON CG Oncology, Inc. | 2,369,574 | $168.4m | 26.2% |
| ALMS ALUMIS INC. | 4,247,670 | $119.5m | 18.6% |
| Seaport Therapeutics, Inc. | 1,779,521 | $38.7m | 6.0% |
| DNLI Denali Therapeutics Inc. | 1,396,771 | $35.9m | 5.6% |
| CLDX Celldex Therapeutics, Inc. | 879,713 | $32.7m | 5.1% |
| AGIO AGIOS PHARMACEUTICALS, INC. | 785,000 | $29.1m | 4.5% |
| CRVS Corvus Pharmaceuticals, Inc. | 1,831,233 | $27.4m | 4.3% |
| PBLS Parabilis Medicines, Inc. | 999,044 | $27.3m | 4.3% |
| GH Research PLC | 940,493 | $25.3m | 3.9% |
| JBIO Jade Biosciences, Inc. | 886,667 | $19.7m | 3.1% |
Get the full book
import finzdata as yf
yf.Client().manager_holdings(cik="2013341")
Every position, quarter by quarter since 2013, with adds, trims and exits, on the look-back bundles.
Get a free API keySee history bundlesDownload free samples